Mission
Antabio has built an international team of experts to understand and resolve the most urgent unmet medical needs of the antibacterial space. We are dedicated to developing a pipeline of novel antibacterial treatments to address infections caused by WHO’s priority pathogens and fill important gaps in the antibiotic armamentarium.
— Marc Lemonnier – CEO, Antabio
Antabio is a clinical-stage biopharmaceutical company focused on the development of innovative, differentiated antibacterial therapies targeting WHO and CDC critical-priority pathogens. Our portfolio addresses the most urgent unmet medical needs in infectious diseases, with a particular emphasis on difficult-to-treat, drug-resistant Gram-negative bacterial infections, and a clear mission to deliver life-saving therapies to patients.
Antabio has built an experienced, international leadership team comprising former executives and managers from Novexel, Pfizer, Merck, GSK, and AstraZeneca. The team brings deep, end-to-end expertise across antibacterial research and development, with a proven track record of advancing assets from early-stage discovery through late-stage clinical trials, and achieving regulatory approvals.
The company also has a strong track record of securing competitive non-dilutive funding, with multi-million-euro awards from the Wellcome Trust, CARB-X, EIC Accelerator, and French governmental programs. Antabio is further supported by leading strategic and institutional investors such as the AMR Action Fund, EIC Fund, BNP Paribas Développement, Turenne/Relyens Santé, and IRDI Capital Investment.